ReviewMediators of inflammation2014
Cytokines as biomarkers in rheumatoid arthritis.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed.
- High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.Arthritis research & therapy · 2020Trial
- Physical Activity Levels and Cardiometabolic Risks in Obese African American Adults: A Pilot Intervention Study.Journal of health care for the poor and underserved · 2018Trial
- An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis.Drug design, development and therapy · 2017Trial
- Trial
- Article
- Production of a risk mitigation matrix and four-grade threshold scale using Cox Regression to predict osteoarthritis development.Open life sciences · 2026Article
- AGTR1 inhibits pyroptosis and inflammatory cytokine secretion in rheumatoid arthritis fibroblast-like synoviocytes through the TGF-β pathway.American journal of translational research · 2026Article
- Validation of a model of rheumatoid arthritis using mice reconstituted with patient peripheral blood mononuclear cells.Disease models & mechanisms · 2025Article
- Rheumatoid Arthritis: Biomarkers and the Latest Breakthroughs.International journal of molecular sciences · 2025Review
- "Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease".NPJ Parkinson's disease · 2025Review
- Dysregulation of Different Modes of Programmed Cell Death in Rheumatoid Arthritis Fibroblast-Like Synoviocyte.International journal of rheumatic diseases · 2025Review
- Circulating Interleukin-6 Levels and Timing of Acute Ischemic Stroke Onset.Annals of clinical and translational neurology · 2025Article
- Salivary and serum biomarkers profile of patients with rheumatoid arthritis and temporomandibular disorders.Clinical rheumatology · 2025Article
- Jamamina: A Green Nanostructured Lipid Carrier with NaDES and Curcumin for Redox Modulation and Inflammatory Disorders.International journal of molecular sciences · 2025Article
- Inflammatory and lipemic response to red meat intake in women with and without Rheumatoid Arthritis: a single meal study within a randomized controlled trial.BMC nutrition · 2025Article
- Expression analysis of inflammatory cytokines in patients with rheumatoid arthritis.Bioinformation · 2025Article
- Predicting multiple sclerosis prognosis using AI and machine learning: integrating clinical, immunological, and radiological variables.Frontiers in neurology · 2025Article
- Eosinophils in Rheumatoid Arthritis: A Multifaceted Role in the Pathogenesis of the Disease.Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2025Article
- Integrating Rehabilitation Services into Routine Care of Rheumatoid Arthritis May Reduce the Inflammatory Response: A Hospital-Based Follow-Up Study in Taiwan.Medicina (Kaunas, Lithuania) · 2024Article
- Multiscale, mechanistic model of Rheumatoid Arthritis to enable decision making in late stage drug development.NPJ systems biology and applications · 2024Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RA is a complex disease that develops as a series of events often referred to as disease continuum. RA would benefit from novel biomarker development for diagnosis where new biomarkers are still needed (even if progresses have been made with the inclusion of ACPA into the ACR/EULAR 2010 diagnostic criteria) and for prognostic notably in at risk of evolution patients with autoantibody-positive arthralgia. Risk biomarkers for rapid evolution or cardiovascular complications are also highly desirable. Monitoring biomarkers would be useful in predicting relapse. Finally, predictive biomarkers for therapy outcome would allow tailoring therapy to the individual. Increasing numbers of cytokines have been involved in RA pathology. Many have the potential as biomarkers in RA especially as their clinical utility is already established in other diseases and could be easily transferable to rheumatology. We will review the current knowledge's relation to cytokine used as biomarker in RA. However, given the complexity and heterogeneous nature of RA, it is unlikely that a single cytokine may provide sufficient discrimination; therefore multiple biomarker signatures may represent more realistic approach for the future of personalised medicine in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.